Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts.

Aims Fibroblast to myofibroblast trans-differentiation with altered bioenergetics precedes cardiac fibrosis (CF). Either prevention of differentiation or promotion of de-differentiation could mitigate CF-related pathologies. We determined whether 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors-statins, commonly prescribed to patients at risk of heart failure (HF)-can de-differentiate myofibroblasts, alter cellular bioenergetics, and impact the human ventricular fibroblasts (hVFs) in HF patients. Methods and results Either in vitro statin treatment of differentiated myofibroblasts (n = 3-6) or hVFs, isolated from human HF patients under statin therapy (HF + statin) vs. without statins (HF) were randomly used (n = 4-12). In vitro, hVFs were differentiated by transforming growth factor-beta 1 (TGF-beta 1) for 72 h (TGF-72 h). Differentiation status and cellular oxygen consumption rate (OCR) were determined by alpha-smooth muscle actin (alpha-SMA) expression and Seahorse assay, respectively. Data are mean +/- SEM except Seahorse (mean +/- SD); P < 0.05, considered significant. In vitro, statins concentration-dependently de-differentiated the myofibroblasts. The respective half-maximal effective concentrations were 729 +/- 13 nmol/L (atorvastatin), 3.6 +/- 1 mu mol/L (rosuvastatin), and 185 +/- 13 nmol/L (simvastatin). Mevalonic acid (300 mu mol/L), the reduced product of HMG-CoA, prevented the statin-induced de-differentiation (alpha-SMA expression: 31.4 +/- 10% vs. 58.6 +/- 12%). Geranylgeranyl pyrophosphate (GGPP, 20 mu mol/L), a cholesterol synthesis-independent HMG-CoA reductase pathway intermediate, completely prevented the statin-induced de-differentiation (alpha-SMA/GAPDH ratios: 0.89 +/- 0.05 [TGF-72 h + 72 h], 0.63 +/- 0.02 [TGF-72 h + simvastatin], and 1.2 +/- 0.08 [TGF-72 h + simvastatin + GGPP]). Cellular metabolism involvement was observed when co-incubation of simvastatin (200 nmol/L) with glibenclamide (10 mu mol/L), a K-ATP channel inhibitor, attenuated the simvastatin-induced de-differentiation (0.84 +/- 0.05). Direct inhibition of mitochondrial respiration by oligomycin (1 ng/mL) also produced a de-differentiation effect (0.33 +/- 0.02). OCR (pmol O-2/min/mu g protein) was significantly decreased in the simvastatin-treated hVFs, including basal (P = 0.002), ATP-linked (P = 0.01), proton leak-linked (P = 0.01), and maximal (P < 0.001). The OCR inhibition was prevented by GGPP (basal OCR [P = 0.02], spare capacity OCR [P = 0.008], and maximal OCR [P = 0.003]). Congruently, hVFs from HF showed an increased population of myofibroblasts while HF + statin group showed significantly reduced cellular respiration (basal OCR [P = 0.021], ATP-linked OCR [P = 0.047], maximal OCR [P = 0.02], and spare capacity OCR [P = 0. 025]) and myofibroblast differentiation (alpha-SMA/GAPDH: 1 +/- 0.19 vs. 0.23 +/- 0.06, P = 0.01). Conclusions This study demonstrates the de-differentiating effect of statins, the underlying GGPP sensitivity, reduced OCR with potential activation of K-ATP channels, and their impact on the differentiation magnitude of hVFs in HF patients. This novel pleiotropic effect of statins may be exploited to reduce excessive CF in patients at risk of HF.